Subscribe to RSS
DOI: 10.1055/s-2004-817931
J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York
Experiences of a Poison Center with Metformin-Associated Lactic Acidosis
Publication History
Received: June 16, 2003
First decision: August 18, 2003
Accepted: October 6, 2003
Publication Date:
04 May 2004 (online)
Abstract
Metformin is widely used in the treatment of type 2 diabetes, though it is recognized to be associated with the risk of lactic acidosis. A case of pronounced lactic acidosis with cardiac arrest (pH 6.60, lactate 17.5 mmol/l, base excess - 30, standard bicarbonate 2.5 mmol/l, core body temperature 27.8 °C) is presented in a 61-year-old woman under metformin therapy. The key laboratory abnormalities observed during the intensive care treatment including repeated hemodialysis are described. The patient showed a complete recovery with residually reduced mental capabilities. Furthermore, an explorative data analysis of our poison center database from 1995 until 2003 concerning metformin was performed. In 109 inquiries for metformin a lactic acidosis (mean pH 6.87 ± 0.11, mean lactate 20.9 ± 8.1 mmol/l) was present in 14 cases (9 female, 5 male, average age 57.7 years) with 8 patients under regular metformin therapy and 6 patients who ingested large amounts of metformin to attempt suicide. 4 patients did not survive the severe metabolic disturbance. The present report demonstrates that metformin-associated lactic acidosis is a rare but critical complication of metformin therapy of type 2 diabetes as well as in acute suicidal ingestion of metformin. Early diagnosis and rapid correction of the metabolic acidosis using hemodialysis provides the possibility of a positive outcome even in severe cases. If metformin-associated lactic acidosis is suspected we recommend early involvement of a poison center.
Key words
Metformin - lactic acidosis - hemodialysis - poison center
References
- 1 Ahmad S, Beckett M. Recovery from pH 6.38: lactic acidosis complicated by hypothermia. Emerg Med J. 2002; 19 169-171
- 2 Bailey C J, Turner R C. Metformin. New Engl J Med. 1996; 334 574-579
- 3 Barrueto F, Meggs W J, Barchman M J. Clearance of metformin by hemofiltration in overdose. J Toxicol Clin Toxicol. 2002; 40 177-180
- 4 Ben M H, Thabet H, Zaghdoudi I, Amamou M. Metformin-associated acute pancreatitis. Vet Hum Toxicol. 2002; 44 47-48
- 5 Berner B, Hummel K M, Strutz F, Ritzel U, Ramadori G, Hagenloch S, Kleine P, Muller G A. Metformin-associated lactic acidosis with acute renal failure in type 2 diabetes mellitus. Med Klin. 2002; 97 99-103
- 6 Campbell I W. Metformin and glibenclamide: comparative risks. Br Med J. 1984; 289 289
- 7 Chang C T, Chen Y C, Fang J T, Huang C C. Metformin associated lactic acidosis: case report and literature review. J Nephrol. 2002 a; 15 398-402
- 8 Chang C T, Chen Y C, Fang J T, Huang C C. High anion gap metabolic acidosis in suicide: don't forget metformin intoxication - two patients' experiences. Ren Fail. 2002 b; 24 671-675
- 9 Gan S C, Barr J, Arieff A I, Pearl R G. Biguanide-associated lactic acidosis: case report and review of the literature. Arch Intern Med. 1992; 152 2333-2336
- 10 Holstein A, Nahrwold D, Hinze S, Egberts E. Contra-indications to metformin therapy are largely disregarded. Diabet Med. 1999; 16 692-696
- 21 Kruse J A. Metformin-associated lactic acidosis. J Emerg Med. 2001; 20 267-272
- 11 Lalau J D, Race J M. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of “metformin-associated lactic acidosis”. Diab Obes Metab. 2001; 3 195-201
- 12 Luft D, Deichsel G, Schmulling R M, Stein N, Eggstein M. Definition of clinically relevant lactic acidosis in patients with internal diseases. Am J Clin Pathol. 1983; 80 484-489
- 13 Spiller H A, Quadrani D A. Five year retrospective review of toxic effects from metformin exposure. J Toxicol Clin Toxicol. 2003; 41 383-564
- 14 Stang M, Wysowski D K, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999; 22 925-927
- 15 UKPDS Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet. 1998; 352 854-865
- 16 von Mach M A, Weilemann L S. Zunehmende Bedeutung von Antidepressiva bei suizidalen und parasuizidalen Intoxikationen. Dtsch Med Wochenschr. 2002; 127 2053-2056
- 17 von Mach M A, Brinkmann C, Hansen T, Weilemann L S, Beyer J. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp Clin Endocrinol Diabetes. 2002; 110 416-419
- 18 von Mach M A, Weilemann L S. Aktuelle Diagnostik von Intoxikationen. Dtsch Med Wochenschr. 2003 a; 128 1121-1123
- 19 von Mach M A, Weilemann L S. Aktuelle Therapie von Intoxikationen. Dtsch Med Wochenschr. 2003 b; 128 1779-1781
- 20 von Mach M A, Lauterbach M, Kaes J, Hengstler J G, Weilemann L S. Suizidale und parasuizidale Intoxikationen mit Paracetamol: Eine Analyse von 1995 bis 2002. Dtsch Med Wochenschr. 2003; 128 15-19
M. D. M.-A. von Mach
II. Medical Department, Poison Center
University Hospitals
Langenbeckstraße 1
55131 Mainz
Germany
Phone: + 496131174154
Fax: + 49 61 31 17 66 05
Email: marcm@giftinfo.uni-mainz.de